These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 2822908)
1. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice. Takemori AE; Portoghese PS J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908 [TBL] [Abstract][Full Text] [Related]
2. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice. Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986 [TBL] [Abstract][Full Text] [Related]
3. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine. Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843 [TBL] [Abstract][Full Text] [Related]
4. Nalbuphine, a mixed kappa 1 and kappa 3 analgesic in mice. Pick CG; Paul D; Pasternak GW J Pharmacol Exp Ther; 1992 Sep; 262(3):1044-50. PubMed ID: 1326621 [TBL] [Abstract][Full Text] [Related]
5. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. Ward SJ; Takemori AE J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119 [TBL] [Abstract][Full Text] [Related]
6. Opioid analgesia in the mouse: evidence for multiple receptors using beta-FNA. Sánchez-Blázquez P; Garzón J NIDA Res Monogr; 1986; 75():465-8. PubMed ID: 2828993 [TBL] [Abstract][Full Text] [Related]
7. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. Adams JU; Paronis CA; Holtzman SG J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793 [TBL] [Abstract][Full Text] [Related]
8. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism. Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070 [TBL] [Abstract][Full Text] [Related]
9. Activity of mu- and delta-selective opioid agonists in the guinea pig ileum preparation: differentiation into peptide and nonpeptide classes with beta-funaltrexamine. Ward SJ; LoPresti D; James DW J Pharmacol Exp Ther; 1986 Aug; 238(2):625-31. PubMed ID: 3016244 [TBL] [Abstract][Full Text] [Related]
10. Intrathecal beta-funaltrexamine antagonizes intracerebroventricular beta-endorphin- but not morphine-induced analgesia in mice. Suh HH; Tseng LF J Pharmacol Exp Ther; 1988 May; 245(2):587-93. PubMed ID: 2966856 [TBL] [Abstract][Full Text] [Related]
11. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. Zimmerman DM; Leander JD; Reel JK; Hynes MD J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213 [TBL] [Abstract][Full Text] [Related]
12. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. Baker AK; Meert TF J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687 [TBL] [Abstract][Full Text] [Related]
13. Examination of the involvement of supraspinal and spinal mu and delta opioid receptors in analgesia using the mu receptor deficient CXBK mouse. Vaught JL; Mathiasen JR; Raffa RB J Pharmacol Exp Ther; 1988 Apr; 245(1):13-6. PubMed ID: 2834533 [TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL; Bartlett JL; Ananthan S; Bilsky EJ J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048 [TBL] [Abstract][Full Text] [Related]
16. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox. Barrett AC; Smith ES; Picker MJ J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297 [TBL] [Abstract][Full Text] [Related]
17. Involvement of spinal kappa opioid receptors in the antinociception produced by intrathecally administered corticotropin-releasing factor in mice. Song ZH; Takemori AE J Pharmacol Exp Ther; 1990 Aug; 254(2):363-8. PubMed ID: 2166788 [TBL] [Abstract][Full Text] [Related]
18. Independent expression of two pharmacologically distinct supraspinal mu analgesic systems in genetically different mouse strains. Pick CG; Nejat RJ; Pasternak GW J Pharmacol Exp Ther; 1993 Apr; 265(1):166-71. PubMed ID: 8386234 [TBL] [Abstract][Full Text] [Related]
19. Role of spinal mu opioid receptors in the development of morphine tolerance and dependence. DeLander GE; Portoghese PS; Takemori AE J Pharmacol Exp Ther; 1984 Oct; 231(1):91-6. PubMed ID: 6092607 [TBL] [Abstract][Full Text] [Related]
20. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes. Tam SW; Liu-Chen LY J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]